SavedAdd your journal

Journals / Eurasian Journal of Biological and Chemical Sciences / 2026 / Volume: 9 Issue: 1

Targeting Antimicrobial-Resistant Diarrhea: Pathogen-Specific and Anti-Virulence Drug Discovery via Molecular Docking

Bekir Çağlar Çelikkaya(University of Strathclyde)0000-0002-8677-9101
Ahmet Ozan Kaleci(Department of Medical Pharmacology, Faculty of Medicine, Sivas Cumhuriyet University, Sivas, TR)0000-0003-4514-6209
Sümeyye İdil Çelikkaya(Department of Pharmacology, Faculty of Pharmacy, Sivas Cumhuriyet University, Sivas, TR)0000-0001-7036-7922
Pages
—
Publication Date
2026-06-28
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, molecular docking approaches could represent a significant advance in combating the growing threat of AMR as a concept.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Infectious diarrhea is an increasing global healthcare issue due to the cause of mortality among children under five caused by pathogens such as bacteria, viruses, and parasites.
📊
Key Findings & Data:Molecular docking strategies, through profiling ligand-target interactions according to their binding affinity, can help to design promising drug candidates and elucidate their mechanisms of action.
💡
Conclusion & Impact:Therefore, molecular docking approaches could represent a significant advance in combating the growing threat of AMR as a concept.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:antimicrobial resistance (AMR) · AMR-associated diarrhea · infectious diarrhea

Abstract

Infectious diarrhea is an increasing global healthcare issue due to the cause of mortality among children under five caused by pathogens such as bacteria, viruses, and parasites. The increasing prevalence of antimicrobial resistance (AMR) has further complicated treatment efforts, highlighting an urgent need for the development of novel therapeutic agents. Antimicrobial chemotherapeutics are often hindered by issues such as gut microbiome disruption and the rising incidence of resistance, highlighting the necessity for pathogen-specific and anti-virulence drug development. This review investigates the wider landscape of AMR-associated diarrhea, focusing on the resistance mechanisms of key pathogens such as Clostridioides difficile and Shigella. It highlights the potential of in silico molecular docking studies as a powerful and efficient computational tool in the drug discovery process by means of accuracy and pathogen-specific drug development. Molecular docking strategies, through profiling ligand-target interactions according to their binding affinity, can help to design promising drug candidates and elucidate their mechanisms of action. Recent studies have shown that the computational docking in screening for inhibitors against drug-resistant targets, paving the way for anti-virulence drug discovery and drug repurposing. This review discusses how some of prospective strategies used by emphasizing the in silico molecular docking methodologies to expedite the development of novel anti-diarrheal drugs with antimicrobial properties. This review outlines how specific AMR targets derived from different microorganisms can be considered as targets for anti-virulence drug development in the context of infectious diarrhea. Therefore, molecular docking approaches could represent a significant advance in combating the growing threat of AMR as a concept.

🔖

Cite This Article

Çelikkaya, B. Ç., Kaleci, A. O., Çelikkaya, S. İ. (2026). Targeting Antimicrobial-Resistant Diarrhea: Pathogen-Specific and Anti-Virulence Drug Discovery via Molecular Docking. Eurasian Journal of Biological and Chemical Sciences, Volume: 9 Issue: 1. https://doi.org/10.46239/ejbcs.1910380

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (86)

  1. Akhondi H, Goldin J, Simonsen KA. 2025. Bacterial diarrhea. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK551643/. Accessed 10 Sept 2025.
  2. Ali HA, Nuh AM, Abdi HA, Muse AH. 2025. Multilevel analysis of prevalence and determinants of diarrhea among under-five children in Somalia: insights from the Somalia demographic and health survey 2020. BMC Public Health. 25(1):21435. doi:10.1186/s12889-025-21435-x.
  3. Ameji PJ, Uzairu A, Shallangwa GA, Uba S. 2023. Molecular docking-based virtual screening, drug-likeness, and pharmacokinetic profiling of some anti-Salmonella typhimurium cephalosporin derivatives. J Taibah Univ Med Sci. 18(6):1417–1431. doi:10.1016/j.jtumed.2023.05.021.
  4. Arya SC. 2002. Nitazoxanide as a broad-spectrum antiparasitic agent. J Infect Dis. 185(11):1692–1692. doi:10.1086/340519.
  5. Bansa R, Zhamutashvili M, Gognadze T, Jojua N, Dolmazishvili E. 2024. Enterohemorrhagic Escherichia coli leading to haemolytic uremic syndrome - case study and review. Georgian Med News. 348:78–80.
  6. Bansal P, Shah D, Meena RK, Rai G, Das S, Narang M, Gupta P. 2023. Shigella as a cause of diarrhea hospitalization in children under five: evaluation by conventional and molecular methods. Cureus. 15(12). doi:10.7759/cureus.50546.
  7. Besser JM. 2018. Salmonella epidemiology: a whirlwind of change. Food Microbiol. 71:55–59. doi:10.1016/j.fm.2017.08.018.
  8. Biswas S, Bal M, Pati S, Rana R, Dixit S, Ranjit M. 2024. Antibiotic resistance in toxigenic E. coli: a severe threat to global health. Discov Med. 1(1):102. doi:10.1007/s44337-024-00102-x.
  9. Black R, Laxminarayan R, Temmerman M, Walker N. 2016. Disease control priorities, third edition, volume 2: reproductive, maternal, newborn, and child health. World Bank Publications. doi:10.1596/978-1-4648-0348-2.
  10. Boysen A, Borch J, Krogh TJ, Hjernø K, Møller-Jensen J. 2015. SILAC-based comparative analysis of pathogenic Escherichia coli secretomes. J Microbiol Methods. 116:66–79. doi:10.1016/j.mimet.2015.06.015.
  11. Burke RM, Mattison CP, Marsh Z, Shioda K, Donald J, Salas SB, Naleway AL, Biggs C, Schmidt MA, Hall AJ. 2021. Norovirus and other viral causes of medically attended acute gastroenteritis across the age spectrum: results from the medically attended acute gastroenteritis study in the United States. Clin Infect Dis. 73(4)–e920. doi:10.1093/cid/ciab033.
  12. Chatterjee S, Lekmeechai S, Constantinou N, Grzybowska EA, Kozik Z, Choudhary JS, Berger CN, Frankel G, Clements A. 2021. The type III secretion system effector EspO of enterohaemorrhagic Escherichia coli inhibits apoptosis through an interaction with HAX-1. Cell Microbiol. 23(9). doi:10.1111/cmi.13366.
  13. Chen G, Seukep AJ, Guo M. 2020. Recent advances in molecular docking for the research and discovery of potential marine drugs. Mar Drugs. 18(11):545. doi:10.3390/md18110545.
  14. Clark DP. 1999. New insights into human cryptosporidiosis. Clin Microbiol Rev. 12(4):554–563. doi:10.1128/cmr.12.4.554.
  15. Dans LF, Martínez EG. 2007. Amoebic dysentery. BMJ Clin Evid. 2007:0918. https://pubmed.ncbi.nlm.nih.gov/19454043/.
  16. Dennehy PH. 2007. Rotavirus vaccines—an update. Vaccine. 25(16):3137–3141. doi:10.1016/j.vaccine.2007.01.102.
  17. Deryabin D, Tolmacheva A. 2015. Antibacterial and anti-quorum sensing molecular composition derived from Quercus cortex (oak bark) extract. Molecules. 20(9):17093–17108. doi:10.3390/molecules200917093.
  18. Dormond M, Gutierrez RL, Porter CK. 2016. Giardia lamblia infection increases risk of chronic gastrointestinal disorders. Trop Dis Travel Med Vaccines. 2(1):13. doi:10.1186/s40794-016-0030-0.
  19. El Qouqa IA, Jarou MAE, Samaha ASA, Afifi ASA, Al Jarousha AMKh. 2011. Yersinia enterocolitica infection among children aged less than 12 years: a case–control study. Int J Infect Dis. 15(1)–e53. doi:10.1016/j.ijid.2010.09.010.
  20. Fonseca-Romero P, Ahmed SM, Brintz BJ, Vierkant DM, Dien Bard J, Cohen DM, Festekjian A, Leber AL, Jackson JT, Kanwar N, Larsen C, Selvarangan R, Chapin KC, Pavia AT, Leung DT, IMPACT study investigators. 2024. Etiologies of bloody diarrhea in children presenting with acute gastroenteritis to US emergency departments. Open Forum Infect Dis. 11(12). doi:10.1093/ofid/ofae692.
  21. Foster TJ. 2017. Antibiotic resistance in Staphylococcus aureus. Current status and future prospects. FEMS Microbiol Rev. 41(3):430–449. doi:10.1093/femsre/fux007.
  22. Gardner TB, Hill DR. 2001. Treatment of giardiasis. Clin Microbiol Rev. 14(1):114–128. doi:10.1128/cmr.14.1.114-128.2001.
  23. Gauba A, Rahman KM. 2023. Evaluation of antibiotic resistance mechanisms in gram-negative bacteria. Antibiotics. 12(11):1590. doi:10.3390/antibiotics12111590.
  24. Golchha NC. 2024. Molecular docking, dynamics and in vitro analysis of multi-target inhibitors for Clostridioides difficile. Bioinformation. 20(1):39–48. doi:10.6026/973206300200039.
  25. Guga G, Elwood S, Kimathi C, Kang G, Kosek MN, Lima AAM, Bessong PO, Samie A, Haque R, Leite JP, Bodhidatta L, Iqbal N, Page N, Kiwelu I, Bhutta ZA, Ahmed T, Liu J, Rogawski McQuade ET, Houpt E, et al. 2022. Burden, clinical characteristics, risk factors, and seasonality of adenovirus 40/41 diarrhea in children in eight low-resource settings. Open Forum Infect Dis. 9(7). doi:10.1093/ofid/ofac241.
  26. Hallowell BD, Tate J, Parashar U. 2020. An overview of rotavirus vaccination programs in developing countries. Expert Rev Vaccines. 19(6):529–537. doi:10.1080/14760584.2020.1775079.
  27. Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. 2012. Cholera. Lancet. 379(9835):2466–2476. doi:10.1016/s0140-6736(12)60436-x.
  28. Hogenauer C, Hammer HF, Krejs GJ, Reisinger EC. 1998. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis. 27(4):702–710. doi:10.1086/514958.
  29. Hu J, Torres AG. 2015. Enteropathogenic Escherichia coli: foe or innocent bystander? Clin Microbiol Infect. 21(8):729–734. doi:10.1016/j.cmi.2015.01.015.
  30. Hung YP, Lee JC, Tsai BY, Wu JL, Liu HC, Liu HC, Lin HJ, Tsai PJ, Ko WC. 2021. Risk factors of Clostridioides difficile-associated diarrhea in hospitalized adults: vary by hospitalized duration. J Microbiol Immunol Infect. 54(2):276–283. doi:10.1016/j.jmii.2019.07.004.
  31. Institute for Health Metrics and Evaluation (IHME). 2024. GBD Compare Data Visualization. http://vizhub.healthdata.org/gbd-compare. Accessed 9 May 2025.
  32. Kaur P, Chakraborti A, Asea A. 2010. Enteroaggregative Escherichia coli: an emerging enteric food borne pathogen. Interdiscip Perspect Infect Dis. 2010:254159. doi:10.1155/2010/254159.
  33. Khalil IA, Troeger C, Blacker BF, Rao PC, Brown A, Atherly DE, Brewer TG, Engmann CM, Houpt ER, Kang G, Kotloff KL, Levine MM, Luby SP, MacLennan CA, Pan WK, Pavlinac PB, Platts-Mills JA, Qadri F, Riddle MS, Reiner RC Jr. 2018. Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990–2016. Lancet Infect Dis. 18(11):1229–1240. doi:10.1016/s1473-3099(18)30475-4.
  34. Lane AB, Copeland NK, Onmus-Leone F, Lawler JV. 2018. Methicillin-resistant Staphylococcus aureus as a probable cause of antibiotic-associated enterocolitis. Case Rep Infect Dis. 2018:3106305. doi:10.1155/2018/3106305.
  35. Lee MS, Koo S, Jeong D, Tesh V. 2016. Shiga toxins as multi-functional proteins: induction of host cellular stress responses, role in pathogenesis and therapeutic applications. Toxins. 8(3):77. doi:10.3390/toxins8030077.
  36. Lohani M, Dhasmana A, Haque S, Wahid M, Jawed A, Dar SA, Mandal RK, Areeshi MY. 2017. Proteome mining for the identification and in-silico characterization of putative drug targets of multi-drug resistant Clostridioides difficile strain 630. J Microbiol Methods. 136:6–10. doi:10.1016/j.mimet.2017.02.008.
  37. Lopes GV, Ramires T, Kleinubing NR, Scheik LK, Fiorentini ÂM, Padilha da Silva W. 2021. Virulence factors of foodborne pathogen Campylobacter jejuni. Microb Pathog. 161:105265. doi:10.1016/j.micpath.2021.105265.
  38. Mainali NR, Quinlan P, Ukaigwe A, Amirishetty S. 2013. Cryptosporidial diarrhea in an immunocompetent adult: role of nitazoxanide. J Community Hosp Intern Med Perspect. 3(3–4):21075. doi:10.3402/jchimp.v3i3-4.21075.
  39. Mare AD, Ciurea CN, Man A, Tudor B, Moldovan V, Decean L, Toma F. 2021. Enteropathogenic Escherichia coli—a summary of the literature. Gastroenterol Insights. 12(1):28–40. doi:10.3390/gastroent12010004.
  40. Marvin SA. 2016. The immune response to astrovirus infection. Viruses. 9(1):1. doi:10.3390/v9010001. McFarland LV. 1998. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis. 16(5):292–307. doi:10.1159/000016879.
  41. McFarland LV. 2008. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 3(5):563–578. doi:10.2217/17460913.3.5.563.
  42. McMillan EA, Jackson CR, Frye JG. 2020. Transferable plasmids of Salmonella enterica associated with antibiotic resistance. Front Microbiol. 10:562. doi:10.3389/fmicb.2020.562181.
  43. Mekonnen SA, Merenstein D, Fraser CM, Marco ML. 2020. Molecular mechanisms of probiotic prevention of antibiotic-associated diarrhea. Curr Opin Biotechnol. 61:226–234. doi:10.1016/j.copbio.2020.01.005.
  44. Mohammed M, Thapa S. 2020. Evaluation of WGS-subtyping methods for epidemiological surveillance of foodborne salmonellosis. One Health Outlook. 2(1):16. doi:10.1186/s42522-020-00016-5.
  45. Mühlen S, Dersch P. 2020. Treatment strategies for infections with Shiga toxin-producing Escherichia coli. Front Cell Infect Microbiol. 10:169. doi:10.3389/fcimb.2020.00169.
  46. Nachamkin I, Allos BM, Ho T. 1998. Campylobacter species and Guillain-Barré syndrome. Clin Microbiol Rev. 11(3):555–567. doi:10.1128/cmr.11.3.555.
  47. Navarre CB, Baird AN, Pugh DG. 2012. Diseases of the gastrointestinal system. In: Pugh DG, Baird AN (eds) Sheep and goat medicine, 2nd edn. Elsevier, pp 71–105. doi:10.1016/b978-1-4377-2353-3.10005-8.
  48. Nemeth V, Pfleghaar N. 2023. Diarrhea. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK448082/. Accessed 10 Sept 2025.
  49. Ochoa TJ, Contreras CA. 2011. Enteropathogenic Escherichia coli infection in children. Curr Opin Infect Dis. 24(5):478–483. doi:10.1097/qco.0b013e32834a8b8b.
  50. Ordóñez-Mena JM, McCarthy ND, Fanshawe TR. 2017. Comparative efficacy of drugs for treating giardiasis: a systematic update of the literature and network meta-analysis of randomized clinical trials. J Antimicrob Chemother. 73(3):596–606. doi:10.1093/jac/dkx430.
  51. Paggi JM, Pandit A, Dror RO. 2024. The art and science of molecular docking. Annu Rev Biochem. 93(1):389–410. doi:10.1146/annurev-biochem-030222-120000.
  52. Pasqua M, Michelacci V, Di Martino ML, Tozzoli R, Grossi M, Colonna B, Morabito S, Prosseda G. 2017. The intriguing evolutionary journey of Enteroinvasive E. coli (EIEC) toward pathogenicity. Front Microbiol. 8:2390. doi:10.3389/fmicb.2017.02390.
  53. Pasupuleti V, Escobedo AA, Deshpande A, Thota P, Roman Y, Hernandez AV. 2014. Efficacy of 5-nitroimidazoles for the treatment of giardiasis: a systematic review of randomized controlled trials. PLoS Negl Trop Dis. 8(3). doi:10.1371/journal.pntd.0002733.
  54. Pinzi L, Rastelli G. 2019. Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci. 20(18):4331. doi:10.3390/ijms20184331.
  55. Popa GL, Popa MI. 2021. Salmonella spp. infection—a continuous threat worldwide. GERMS. 11(1):88–96. doi:10.18683/germs.2021.1244.
  56. Rajput P, Nahar KS, Rahman KM. 2024. Evaluation of antibiotic resistance mechanisms in gram-positive bacteria. Antibiotics. 13(12):1197. doi:10.3390/antibiotics13121197.
  57. Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, Cohen H. 2020. Antibiotics as major disruptors of gut microbiota. Front Cell Infect Microbiol. 10:572912. doi:10.3389/fcimb.2020.572912.
  58. Rausch-Phung EA, Nguyen AD, Aziz M. 2025. Enterohemorrhagic Escherichia coli. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK519509/. Accessed 10 Sept 2025.
  59. Rohde CL, Bartolini V, Jones N. 2009. The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridioides difficile-associated diarrhea. Nutr Clin Pract. 24(1):33–40. doi:10.1177/0884533608329297.
  60. Rossignol JF. 2014. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 110:94–103. doi:10.1016/j.antiviral.2014.07.014.
  61. Selvaraj V, Alsamman MA. 2022. Antibiotic-associated diarrhea beyond C. difficile: a scoping review. J Brown Hosp Med. 2(1). doi:10.56305/001c.39745.
  62. Shen H, Liu S, Shang L, Liu Y, Sha Y, Lei D, Zhang Y, Jin C, Wu S, Zhang M, Wen H, Jia C, Wang J. 2025. Discovery of small-molecule inhibitors against norovirus 3CLpro using structure-based virtual screening and flipgfp assay. Viruses. 17(6):814. doi:10.3390/v17060814.
  63. Shen-Tu G, Schauer DB, Jones NL, Sherman PM. 2010. Detergent-resistant microdomains mediate activation of host cell signaling in response to attaching–effacing bacteria. Lab Invest. 90(2):266–281. doi:10.1038/labinvest.2009.131.
  64. Siamalube B, Ehinmitan E. 2025. Vibrio cholerae: understanding a persistent pathogen in Sub-Saharan Africa and the East Mediterranean Region. Pathog Dis. 83(1). doi:10.1093/femspd/ftaf004.
  65. Solís-Sánchez P, Fernández-Martínez M, Rodrigo-Calabia E, de Alegría-Puig CR. 2023. Chronic diarrhea due to Aeromonas hydrophila in an immunosuppressed patient with a pancreas–kidney transplant. Pathogens. 12(9):1151. doi:10.3390/pathogens12091151.
  66. Tan M. 2021. Norovirus vaccines: current clinical development and challenges. Pathogens. 10(12):1641. doi:10.3390/pathogens10121641.
  67. Tarín-Pelló A, Fernández-Álvarez S, Suay-García B, Pérez-Gracia MT. 2025. Novel antimicrobials from computational modelling and drug repositioning: potential in silico strategies to increase therapeutic arsenal against antimicrobial resistance. Molecules. 30(11):2303. doi:10.3390/molecules30112303.
  68. Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. 2016. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. Clin Infect Dis. 62(Suppl 2)–S105. doi:10.1093/cid/civ1013.
  69. Thorne L, Arias A, Goodfellow I. 2016. Advances toward a norovirus antiviral: from classical inhibitors to lethal mutagenesis. J Infect Dis. 213(Suppl 1)–S31. doi:10.1093/infdis/jiv280.
  70. Todd S, Page NA, Steele AD, Peenze I, Cunliffe NA. 2010. Rotavirus strain types circulating in Africa: review of studies published during 1997–2006. J Infect Dis. 202(S1)–S42. doi:10.1086/653555.
  71. Traa BS, Walker CLF, Munos M, Black RE. 2010. Antibiotics for the treatment of dysentery in children. Int J Epidemiol. 39(Suppl 1)–i74. doi:10.1093/ije/dyq024.
  72. Tribble DR. 2017. Antibiotic therapy for acute watery diarrhea and dysentery. Mil Med. 182(S2):17–25. doi:10.7205/milmed-d-17-00068.
  73. Troeger C, Forouzanfar M, Rao PC, Khalil I, Brown A, Reiner RC Jr, Fullman N, Thompson RL, Abajobir A, Ahmed M, Alemayohu MA, Alvis-Guzman N, Amare AT, Antonio CA, Asayesh H, Avokpaho E, Awasthi A, Bacha U, Barac A, et al. 2017. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 17(9):909–948. doi:10.1016/s1473-3099(17)30276-1.
  74. Uddin TM, Chakraborty AJ, Khusro A, Zidan BRM, Mitra S, Emran TB, Dhama K, Ripon MdKH, Gajdács M, Sahibzada MUK, Hossain MdJ, Koirala N. 2021. Antibiotic resistance in microbes: history, mechanisms, therapeutic strategies and future prospects. J Infect Public Health. 14(12):1750–1766. doi:10.1016/j.jiph.2021.10.020.
  75. Varughese CA, Vakil NH, Phillips KM. 2013. Antibiotic-associated diarrhea. J Pharm Pract. 26(5):476–482. doi:10.1177/0897190013499523.
  76. Wang E, Sun H, Wang J, Wang Z, Liu H, Zhang JZ, Hou T. 2019. End-point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design. Chem Rev. 119(16):9478–9508. doi:10.1021/acs.chemrev.9b00055.
  77. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FT, de Beer TAP, Rempfer C, Bordoli L, Lepore R, Schwede T. 2018. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 46(W1)–W303. doi:10.1093/nar/gky427.
  78. Wickramage I, Spigaglia P, Sun X. 2021. Mechanisms of antibiotic resistance of Clostridioides difficile. J Antimicrob Chemother. 76(12):3077–3090. doi:10.1093/jac/dkab231.
  79. World Health Organization. 2025. Global antibiotic resistance surveillance report 2025. https://www.who.int/publications/i/item/9789240116337.
  80. Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, Yin M, Zeng X, Wu C, Lu A, Chen X, Hou T, Cao D. 2021. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 49(W1)–W14. doi:10.1093/nar/gkab255.
  81. Yang H, Ruan X, Li W, Xiong J, Zheng Y. 2024. Global, regional, and national burden of tuberculosis and attributable risk factors for 204 countries and territories, 1990–2021: a systematic analysis for the Global Burden of Diseases 2021 study. BMC Public Health. 24(1):708. doi:10.1186/s12889-024-20664-w.
  82. Yassine I, Hansen EE, Lefèvre S, Ruckly C, Carle I, Lejay-Collin M, Fabre L, Rafei R, Pardos de la Gandara M, Daboussi F, Shahin A, Weill FX. 2023. ShigaPass: an in silico tool predicting Shigella serotypes from whole-genome sequencing assemblies. Microb Genom. 9(3):000961. doi:10.1099/mgen.0.000961.
  83. Ydsten KA, Hellgren U, Asgeirsson H. 2021. Quinacrine treatment of nitroimidazole-refractory giardiasis. J Infect Dis. 225(10):1773–1776. doi:10.1093/infdis/jiab287.
  84. Yoon HY, Cho HH, Ryu YJ. 2019. Adenovirus pneumonia treated with Cidofovir in an immunocompetent high school senior. Respir Med Case Rep. 26:215–218. doi:10.1016/j.rmcr.2019.01.015.
  85. Yu Q, Zhang Z, Liu G, Li W, Tang Y. 2024. ToxGIN: an in silico prediction model for peptide toxicity via graph isomorphism networks integrating peptide sequence and structure information. Brief Bioinform. 25(6). doi:10.1093/bib/bbae583.
  86. Zhou K, Sun L, Zhang X, Xu X, Mi K, Ma W, Zhang L, Huang L. 2023. Salmonella antimicrobials inherited and the non-inherited resistance: mechanisms and alternative therapeutic strategies. Front Microbiol. 14:1176317. doi:10.3389/fmicb.2023.1176317.